Free Trial

BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals logo with Medical background

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its earnings results on Monday. The biotechnology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27, Briefing.com reports. The company had revenue of $145.53 million during the quarter, compared to analyst estimates of $126.83 million. During the same period in the previous year, the company earned ($0.17) EPS. The company's quarterly revenue was up 56.8% compared to the same quarter last year.

BioCryst Pharmaceuticals Trading Up 0.6 %

BCRX stock traded up $0.06 during trading on Friday, hitting $9.98. 7,606,302 shares of the company's stock were exchanged, compared to its average volume of 2,991,433. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals has a 52-week low of $5.23 and a 52-week high of $11.11. The business has a 50-day moving average price of $7.87 and a two-hundred day moving average price of $7.89.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BCRX shares. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday. Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Finally, Barclays increased their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.56.

View Our Latest Research Report on BCRX

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?

Before you consider BioCryst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.

While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines